Clinical trials: Colonic Diseases, Functional
Irritable Bowel Syndrome (IBS)
Study to Evaluate the Effects of ONO-2952 on Pain Perception Produced by Rectal Distention in Female Subjects With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D)
The objective is to evaluate whether ONO-2952 modulates visceral pain perception produced by rectal distention in female patients with IBS-D
- Trial name
- RESTORE (NCT01887002)
- Testing
- ONO-2952
- Where
- 4 sites in United States
- Volunteers
- 39 people
- Sponsor
- Ono Pharma USA Inc
Myalgic Encephalomyelitis, Chronic Fatigue Syndrome
Effect of Probiotics in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS)
Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) is a neurological disease. Currently there is no effective treatment for ME/CFS due to unclear etiology of the disease.
- Trial name
- NCT04741841
- Testing
- GutMagnific™ H., GutMagnific™ L.
- Where
- Sweden
- Volunteers
- 74 people
- Sponsor
- ImmuneBiotech Medical Sweden AB
Irritable Bowel Syndrome
Comparison of the Efficacy and Safety of Tiropramide and Octylonium in the Treatment of Irritable Bowel Syndrome
The purpose of this study was to compare the Efficacy and Safety of Tiropramide HCl and Octylonium bromide in the Treatment of Irritable Bowel Syndrome.
- Trial name
- NCT01629212
- Testing
- Tiropramide HCl 100mg, Octylonium bromide 20mg
- Where
- South Korea
- Sponsor
- Daewoong Pharmaceutical Co. LTD.
Irritable Bowel Syndrome, Crohn Disease
Evaluation of the SIMBA Capsule for Small Intestinal Dysbiosis
The SIMBA Capsule is a small, single-use, ingestible capsule that allows for the non-invasive sampling of small bowel contents using purely mechanical means.
- Conditions
- Irritable Bowel Syndrome, Crohn Disease, Celiac Disease, Ulcerative Colitis
- Trial name
- NCT05633706
- Testing
- fluid biopsy capsule
- Where
- Canada
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Nimble Science Ltd.
Irritable Bowel Syndrome
EFESO - EFficacy Enterogermina Small Intestinal Bacterial Overgrowth
Primary objective: to assess the efficacy of Bacillus clausii versus metronidazole in the eradication of the small intestinal bacterial overgrowth, 30 days after the end of treatment.
- Trial name
- NCT00331994
- Testing
- Bacillus clausii, Metronidazole
- Where
- Italy
- Volunteers
- 250 people
- Sponsor
- Sanofi
Irritable Bowel Syndrome
Safety and Efficacy Study of PEA and Polydatin on Intestinal Inflammation and Visceral Hyperalgesia in IBS Patients
Despite the pathophysiology of IBS remains largely unsettled, several mechanisms have been proposed to explain symptom generation.
- Trial name
- CMD-IBS09(2) (NCT01370720)
- Testing
- Recoclix
- Where
- Italy
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- MARIA CRISTINA COMELLI
Irritable Bowel Syndrome (IBS)
Effects of HMOs on Faecal Microbiota, Gastrointestinal Symptoms, Mucosal Immunity and Barrier Function in IBS Patients
The study is a randomised, placebo-controlled, double-blind parallel study in IBS patients. A total of 60 adult patients diagnosed with IBS-C, -D or -A/M according to Rome IV criteria will be included.
- Trial name
- NCT02875847
- Testing
- HMO1, HMO2, Dextropur
- Where
- Sweden
- Volunteers
- 60 people
- Sponsor
- Glycom A/S
Irritable Bowel Syndrome (IBS)
Pilot Study to Assess the Effects of AV608 on Irritable Bowel Syndrome
The purpose of this study is to assess the effects of AV608, a neurokinin 1 (NK-1) antagonist, in subjects with Irritable Bowel Syndrome.
- Trial name
- NCT00316550
- Testing
- AV608
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Avera Pharmaceuticals
Irritable Bowel Syndrome (IBS)
Irritable Bowel Syndrome Survey in Gastroenterological Adult Outpatients in China
The primary objective of this study is to estimate the overall prevalence of IBS medically diagnosed and diagnosed using Rome III or IV criteria in GI adult outpatients in China.
- Trial name
- IRONS (NCT02955316)
- Where
- China
- Volunteers
- 3,000 people
- Sponsor
- AstraZeneca
Irritable Bowel Syndrome
A 14-week Pilot Prospective Clinical Trial With BiOkuris Product in Patients With Irritable Bowel Syndrome
Irritable Bowel Syndrome (IBS) is a common chronic gastrointestinal condition that affects approximately 10-20% of adults in Western countries.
- Trial name
- NCT05780749
- Testing
- DDI-IBS-001
- Where
- 11 sites in Belgium
- Volunteers
- 116 people
- Sponsor
- Biokuris s.a.
IBS (Irritable Bowel Syndrome)
A Prospective Trial of a Variable Compression System for Moderate to Severe Irritable Bowel Syndrome
This prospective, interventional trial is intended to determine the safety and effectiveness of the Variable Compression System (VCS) device for Irritable Bowel Syndrome (IBS).
- Trial name
- NCT07540312
- Testing
- Variable Compression System
- Where
- 3 sites in United States
- Volunteers
- 20 people
- Sponsor
- PGP Health
Ulcerative Colitis, Crohn Disease
Systems Biology of Gastrointestinal and Related Diseases
This is a longitudinal observational study on patients with gastrointestinal and related disease. The study will be conducted for at least 10 years, following each participant over time, as they either go through relapses and…
- Conditions
- Ulcerative Colitis, Crohn Disease, Obesity, Colon Polyp
- Trial name
- NCT05579444
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Viome
Irritable Bowel Syndrome, Relief of Irritable Bowel Syndrome Symptoms
Effects of Cultura Yoghurt in Irritable Bowel Syndrome (IBS) Patients on Intestinal and Immunological Changes
To determine the effect of cultura probiotic yoghurt on number of responders to treatment during 8 weeks of treatment in comparison to placebo.
- Conditions
- Irritable Bowel Syndrome, Relief of Irritable Bowel Syndrome Symptoms, Quality of Life
- Trial name
- NCT01127828
- Testing
- Arla Yoghurt with no probiotic, Probiotic yoghurt (Cultura)
- Where
- Sweden
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Good Food Practice, Sweden
Irritable Bowel Syndrome
Efficacy, Safety, and Tolerability of JNJ-27018966 (Eluxadoline) in the Treatment of Irritable Bowel Syndrome With Diarrhea
The purpose of this study is to determine the efficacy, safety, and tolerability of different doses of JNJ-27018966 (eluxadoline) compared with placebo in the treatment of patients with irritable bowel syndrome with diarrhea…
- Trial name
- NCT01130272
- Testing
- Eluxadoline
- Where
- 288 sites in United States
- Volunteers
- 807 people
- Sponsor
- Furiex Pharmaceuticals, Inc
Irritable Bowel Syndrome
Effect of BIO-K+ on Symptoms of Irritable Bowel Syndrome
The purpose of this study is to evaluate the safety and effectiveness of Bio-K+ on symptoms of IBS.
- Trial name
- NCT01545037
- Testing
- L. acidophilus CL1285® + L. casei LBC80R® + L. rhamnosus CLR2®
- Where
- 3 sites in United States
- Volunteers
- 117 people, healthy volunteers welcome
- Sponsor
- Bio-K Plus International Inc.
Irritable Bowel Syndrome
Effectiveness of On-demand Meteospasmyl® Use in Irritable Bowel Syndrome (IBS)
The purpose of this study is to compare the effectiveness of 2 IBS treatment strategies: Strategy A = MeteoSpasmyl®, on-demand therapy Strategy B = standard of care chosen by the physician
- Trial name
- NCT01404923
- Testing
- anti spasmodic agents, alverine citrate, simeticone
- Volunteers
- 436 people
- Sponsor
- Laboratoires Mayoly Spindler
Irritable Bowel Syndrome
Effects of a Food Supplement Composed by BIOintestil ® (Bionocol®) on Microbiota and Inflammatory Profile in Irritable Bowel Syndrome Patients
The aim of this double blind placebo-controlled study is to evaluate the effect of BIOintestil on fecal microbiota, inflammatory chemokines and symptoms in patients affected by Irritable Bowel Syndrome (IBS).
- Trial name
- NCT04340661
- Testing
- BIOintestil
- Where
- Italy
- Volunteers
- 56 people
- Sponsor
- Targeting Gut Disease S.R.L.
Irritable Bowel Syndrome
Evaluation of the Efficacy of Two Probiotic Strains for Irritable Bowel Syndrome
The purpose of this study is to determine if two different probiotic strains, Lactobacillus paracasei HA-196 and Bifidobacterium longum R0175, are effective in helping subjects manage the symptoms of IBS
- Trial name
- 14PIHL (NCT02213172)
- Testing
- Bifidobacterium longum R0175, Lactobacillus paracasei HA-196
- Where
- Canada
- Volunteers
- 285 people
- Sponsor
- KGK Science Inc.
Irritable Bowel Syndrome
Study of LX1031 in Subjects With Non-Constipating Irritable Bowel Syndrome
The purpose of the study is to evaluate the safety, tolerability, and effectiveness of LX1031 versus a placebo control in subjects with non-constipating irritable bowel syndrome.
- Trial name
- NCT00813098
- Testing
- LX1031 High Dose, LX1031 Low Dose
- Where
- 36 sites in United States
- Volunteers
- 155 people
- Sponsor
- Lexicon Pharmaceuticals
Irritable Bowel Syndrome
Study to Evaluate the Role of Itopride HCI in Patients With Irritable Bowel Syndrome With Predominant Constipation
Patients suffering from Irritable Bowel Syndrome with predominant constipation will be provided with the study medication. The study medication will be evaluated for its efficacy in relieving the symptoms
- Trial name
- NCT01027260
- Testing
- Itopride HCI 50 mg, Itopride HCI 100 mg
- Where
- 4 sites in Pakistan
- Volunteers
- 268 people
- Sponsor
- Abbott